Table 1 Descriptives of GMS groups at timepoint 1.

From: Nine-year follow-up of 24-hour movement behaviors and glucose metabolism status among adults from the Maastricht study

 

Stable NG (n = 975)

Stable IGM (n = 89)

Stable T2DM (n = 282)

Progression to IGM (n = 166)

Progression to T2DM (n = 111)

Improvers (n = 101)

p-value

Age (years)

58.00 [52.00, 63.00]b, c,d, e,f

63.00 [59.00, 68.00]a

63.00 [57.00, 67.00]a

62.00 [56.00, 66.00]a

60.29 (6.88)a

60.06 (7.78)a

< 0.001

Female (%)

580 ( 59.5)c, f

45 ( 50.6)c

67 ( 23.8)a, b,d, e,f

90 ( 54.2)c

50 ( 45.0)c

43 ( 42.6)a, c

< 0.001

Educational level (%)

      

0.071

 Low

231 ( 24.1)

23 ( 26.1)

92 ( 33.5)

41 ( 24.8)

34 ( 30.6)

27 ( 27.0)

 Mid

273 ( 28.4)

31 ( 35.2)

83 ( 30.2)

51 ( 30.9)

28 ( 25.2)

27 ( 27.0)

 High

456 ( 47.5)

34 ( 38.6)

100 ( 36.4)

73 ( 44.2)

49 ( 44.1)

46 ( 46.0)

 Missing

15

1

7

1

 

1

 

Smoking status (%)

      

0.001

 Never (1)

420 ( 43.3)c

24 ( 27.3)

88 ( 31.9)a

77 ( 46.7)

47 ( 42.3)

32 ( 32.0)

 Former (2)

468 ( 48.3)c

59 ( 67.0)

157 ( 56.9)a

75 ( 45.5)

53 ( 47.7)

63 ( 63.0)

 Current (3)

81 ( 8.4)c

5 ( 5.7)

31 ( 11.2)a

13 ( 7.9)

11 ( 9.9)

5 ( 5.0)

 Missing

6

1

3

1

 

1

Alcohol (%)

      

0.107

 None (1)

123 ( 12.7)

12 ( 13.6)

50 ( 18.1)

20 ( 12.1)

17 ( 15.3)

13 ( 13.0)

 Low (women:≤7; men:≤14) (2)

590 ( 61.0)

50 ( 56.8)

163 ( 59.1)

91 ( 55.2)

55 ( 49.5)

55 ( 55.0)

 High women > 7; men > 14) (3)

255 ( 26.3)

26 ( 29.5)

63 ( 22.8)

54 ( 32.7)

39 ( 35.1)

32 ( 32.0)

 Missing

7

1

6

1

 

1

DHD15

85.60 [75.95, 96.65]c

84.25 [71.58, 93.20]

82.20 [70.70, 90.42]a

86.88 [76.37, 95.01]

80.70 [68.79, 93.16]

83.94 [74.82, 94.18]

< 0.001

 Missing

19

6

 

4

4

1

BMI (kg/m2)

24.70 [22.80, 26.80]b, c,d, e,f

26.80 [24.70, 29.50]a, c

28.70 [25.90, 31.48]a, b,d, f

26.37 (3.21)a, c

27.40 [25.15, 30.05]a

26.00 [23.90, 28.50]a, c

< 0.001

WC (cm)

88.20 [80.45, 95.40]b, c,d, e,f

96.25 (11.36)a, c

104.55 [95.32, 112.22]a, b,d, e,f

93.41 (10.11)a, c,e

98.63 (11.73)a, c,d

93.40 [86.00, 101.50]a, c

< 0.001

WHR

0.89 [0.83, 0.96]b, c,d, e,f

0.94 (0.08)a, c

1.02 [0.96, 1.07]a, b,d, e,f

0.93 (0.08)a, c,e

0.96 (0.08)a, c,d

0.93 (0.09)a, c

< 0.001

 Missing

4

  

2

 

1

 

Systolic blood pressure (mmHg)

128.00 [117.00, 140.00]b, c,d, e,f

138.02 (17.87)a

141.26 (17.15)a, d,f

134.20 (17.56)a, c

139.23 (17.00)a

133.90 (15.85)a, c

< 0.001

Diastolic blood pressure (mmHg)

74.00 [68.00, 80.00]c, e

76.90 (8.75)e

77.02 (9.70)a

76.05 (10.69)e

79.75 (9.95)a, d

76.28 (8.73)

< 0.001

HDL-cholesterol (mmol/L)

1.70 [1.40, 2.00]b, c,e, f

1.50 [1.20, 1.70]a, c

1.20 [1.00, 1.40]a, b,d, e,f

1.60 [1.30, 1.90]c, e,f

1.40 [1.20, 1.65]a, c,d, e,f

1.50 [1.20, 1.8]a, c,e

< 0.001

LDL-cholesterol (mmol/L)

3.30 [2.70, 3.90]c

3.39 (0.99)c

2.30 [1.80, 2.90]a, b,d, e,f

3.37 (0.92)c

3.26 (1.05)c

3.00 [2.50, 3.6]c

< 0.001

Triglycerides (mmol/L)

1.03 [0.78, 1.37]b, c,d, e,f

1.41 [0.99, 2.01]a

1.51 [1.13, 2.31]a, d

1.23 [0.90, 1.62]a, c,e

1.53 [1.06, 1.96]a, d

1.31 [1.03, 1.76]a

< 0.001

Fasting glucose (mmol/L)

5.10 [4.80, 5.40]b, c,d, e,f

5.90 [5.40, 6.20]a, c,d

7.40 [6.80, 8.38]a, b,d, e,f

5.40 [5.10, 5.70]a, b,c, e,f

5.90 [5.50, 6.20]a, c,d

5.60 [5.30,6.1]a, c,d

< 0.001

2 h-glucose (mmol/L)

5.10 [4.30, 5.80]b, c,d, e,f

8.23 (1.42)a, c,d

14.53 (3.56)a, b,d, e,f

6.00 [5.00, 6.90]a, b,c, e,f

7.74 (1.83)a, c,d

8.40 [7.80, 8.9]a, c,d

< 0.001

 Missing

7

 

52

1

 

1

 

HbA1c (mmol/mol)

35.00 [32.00, 37.00]b, c,d, e,f

37.58 (3.37)a, c

49.00 [45.00, 54.00]a, b,d, e,f

36.81 (3.24)a, c

39.00 [36.00, 42.00]a, c

36.57 (4.40)a, c

< 0.001

 Missing

  

1

1

   

Duration T2DM (years)

NaN (NA)

NaN (NA)

4.00 [1.00, 9.00]

NaN (NA)

NaN (NA)

NaN (NA)

 

Glucose lowering mediation = yes (%)

0 (0.0)c

0 (0.0)c

215 (76.2)a, b,d, e,f

0 (0.0)c

0 (0.0)c

5 (5.0)a, b,c, d,e

< 0.001

Blood pressure lowering medication = yes (%)

177 (18.2)b, c,e, f

30 (33.7)a, c

187 (66.3)a, b,d, f

47 (28.3)c, e

59 (53.2)a, d

45 (44.6)a, c

< 0.001

Lipid lowering medication = yes (%)

116 (11.9)b, c,d, e,f

29 (32.6)a, c

204 (72.3)a, b,d, e,f

40 (24.1)a, c

45 (40.5)a, c

31 (30.7)a, c

< 0.001

Current depression (MINI) = yes (1) (%)

20 (2.1)

1 (1.2)

8 (3.0)

3 (1.8)

3 (2.8)

6 (6.2)

0.207

 Missing

32

6

12

3

2

4

 

PHQ9

2.00 [0.00, 4.00]

1.00 [0.00, 3.00]

1.00 [0.00, 3.00]

2.00 [0.00, 3.00]

1.00 [0.00, 4.00]

2.00 [0.00, 4.00]

0.168

 Missing

38

4

19

7

3

4

 

SF36 PCS

54.09 [49.37, 56.63]c

53.52 [50.27, 55.69]

52.01 [47.35, 54.91]a, d,f

53.33 [49.55, 56.48]c

53.57 [49.32, 55.92]

53.93 [48.52, 56.68]c

< 0.001

 Missing

11

1

10

1

 

1

 

SF36 MCS

55.59 [51.14, 58.44]c

55.11 [51.08, 58.40]

56.79 [53.06, 59.08]a

56.09 [53.53, 58.58]

55.94 [52.19, 58.86]

56.23 [51.72, 58.30]

0.015

 Missing

11

1

10

1

 

1

 
  1. BMI body mass index, WC waist circumference, WHR waist to hip ratio, DHD15 Dutch Healthy Diet Index 2015, PHQ9 patient health questionnaire-9, SF36 PCS 36-item short from health survey Physical component score, SF36 MCS 36-item short from health survey Mental Component Score, NG normoglycemia, IGM impaired glucose metabolism, T2DM type 2 diabetes mellitus.
  2. Continuous variables represented by mean (± standard deviation) for normally distributed variables, and median and [interquartile range] for not normally distributed variables. Categorical variables represented by number and percentage.
  3. Between group differences (bold values p < 0.05). Group (one-by-one) differences with Bonferroni correction (0.05/15 = 0.003). A Chi Square test was used to explore differences between categorical variables, followed by a pairwise Chi-square for post-hoc testing. A One-Way Manova was used to explore differences between the six groups for normally distributed variables followed by Tukey HSD for posthoc testing. A Kruskal-Wallis test was used for not-normally distributed variables followed by Dunn’s test for post-hoc testing.
  4. aMeans significantly different compared to the Stable NG group, bmeans significantly different compared to the Stable IGM group, cmeans significantly different compared to the Stable T2DM group, dmeans significantly different compared to the Progression to IGM group, emeans significantly different compared to the Progression to T2DM group, fmeans significantly different compared to the Improvers group.